Cargando…

Darunavir-based dual therapy in HIV experienced patients

BACKGROUND: We assessed the virological response of DRV/r-based dual therapy in drug-experienced patients included in the Italian antiretroviral resistance database (ARCA). MATERIALS AND METHODS: Patients included in the study were treated with DRV/r in association with raltegravir (RAL), etravirine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sterrantino, Gaetana, Zaccarelli, Mauro, Di Biagio, Antonio, Rosi, Andrea, Bruzzone, Bianca, Cicconi, Paola, Carli, Tiziana, Luisa Biondi, Maria, Antinori, Andrea, Bartolozzi, Dario, Penco, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P250
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225358/ https://www.ncbi.nlm.nih.gov/pubmed/25397526 http://dx.doi.org/10.7448/IAS.17.4.19782

Ejemplares similares

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Syndrome de Sweet secondaire à une infection sévère à SARS-CoV-2
por: Berro, Simar, et al.
Publicado: (2021)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Consultations de pneumologie dans un secteur public d’Annaba (Algérie) : influence de l’infection à SARS-CoV-2
por: Yakoubi, R., et al.
Publicado: (2022)

Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era
por: Sterrantino, G, et al.
Publicado: (2012)

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy
por: Antinori, Andrea, et al.
Publicado: (2014)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis
por: Zaccarelli, Mauro, et al.
Publicado: (2014)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era
por: Sterrantino, Gaetana, et al.
Publicado: (2012)

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
por: Borghetti, Alberto, et al.
Publicado: (2014)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up
por: Lanzafame, Massimiliano, et al.
Publicado: (2014)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients
por: Berno, Giulia, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Prevalence of anal human papillomavirus infection and cytologic abnormalities among HIV-infected and HIV-uninfected men who have sex with men
por: Latini, Alessandra, et al.
Publicado: (2014)

Central nervous system penetration-effectiveness rank does not reliably predict neurocognitive impairment in HIV-infected individuals
por: Libertone, Raffaella, et al.
Publicado: (2014)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

Relationship between body mass index and bone mineral density in HIV-infected patients referred for DXA
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort
por: Di Biagio, Antonio, et al.
Publicado: (2014)

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach
por: Dickinson, Laura, et al.
Publicado: (2014)

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults
por: Tashima, Karen, et al.
Publicado: (2014)

Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL
por: Dentone, Chiara, et al.
Publicado: (2014)

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
por: Neely, Michael, et al.
Publicado: (2009)

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
por: Gianotti, Nicola, et al.
Publicado: (2014)

King's Fund Emergency Distribution
Publicado: (1920)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009)

Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
por: Schultze, Anna, et al.
Publicado: (2014)

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gq89sv2ni8jeb0beim4ljns8ig